Envestnet Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Envestnet Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Buy	33,272 +219	+0.7%	+$7.07K	﹤0.01%	3495
2026 Q1	$1.05M	Sell	33,053 -16,023	-33%	-$437K	﹤0.01%	3447
2025 Q4	$1.33M	Sell	49,076 -14,518	-23%	-$382K	﹤0.01%	3113
2025 Q3	$1.65M	Buy	63,594 +21,307	+50%	+$494K	﹤0.01%	3009
2025 Q2	$861K	Buy	+42,287	New	+$823K	﹤0.01%	3363
2014 Q4	–	Sell	-2	Closed	–	–	2525
2014 Q3	$0	Hold	2	–	–	﹤0.01%	2755
2014 Q2	$0	Hold	2	–	–	﹤0.01%	2713
2014 Q1	$0	Hold	2	–	–	﹤0.01%	2557
2013 Q4	$1K	Buy	+2	New	+$770	﹤0.01%	2328

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Envestnet Asset Management's CLDX Position: Q2 2026 in Review

Envestnet Asset Management increased its Celldex Therapeutics (CLDX) stake by 0.66% in Q2 2026, buying an estimated $7.07K and bringing the position to 33,272 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3495.

Envestnet Asset Management first reported a position in CLDX in Q4 2013 and has held it in 9 quarters since. The position peaked at $1.65M in Q3 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Envestnet Asset Management held 33,272 shares of Celldex Therapeutics worth $1.24M as of Q2 2026.
Envestnet Asset Management bought 219 Celldex Therapeutics shares in Q2 2026, an estimated $7.07K.
Celldex Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3495 holding.
Envestnet Asset Management first reported a position in Celldex Therapeutics in Q4 2013 and has held it in 9 quarters since.
Envestnet Asset Management's Celldex Therapeutics position peaked at $1.65M in Q3 2025.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.